{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:03:11Z","timestamp":1794873791772,"version":"4.9.1"},"reference-count":149,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:00:00Z","timestamp":1759622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Pain remains one of the most burdensome symptoms in rheumatoid arthritis (RA), often persisting despite inflammatory remission and profoundly impairing quality of life. This review aimed to evaluate the clinical efficacy and mechanistic pathways by which Janus kinase (JAK) inhibitors alleviate RA-related pain. Evidence from randomized clinical trials demonstrates that JAK inhibitors have demonstrated rapid and significant pain relief, often exceeding that of methotrexate or biologic DMARDs. Improvements in patient-reported pain scores seem to typically emerge within 1\u20132 weeks and are sustained over time. Beyond anti-inflammatory effects, JAK inhibitors modulate central sensitization and nociceptive signaling by attenuating IL-6 and GM-CSF activity, reducing astrocyte and microglial activation, and downregulating nociceptor excitability in dorsal root ganglia and spinal pathways. Preclinical models further suggest that JAK inhibition interrupts neuroimmune feedback loops critical to chronic pain maintenance. Comparative and network meta-analyses consistently position JAK inhibitors among the most effective agents for pain control in RA. However, individual variability in response, partly due to differential JAK-STAT activation and cytokine receptor uncoupling, underscores the need for biomarker-guided treatment approaches. JAK inhibitors represent a mechanistically distinct and clinically impactful class of therapies that target both inflammatory and non-inflammatory pain in RA. Their integration into personalized pain management strategies offers a promising path to address one of RA\u2019s most persistent unmet needs.<\/jats:p>","DOI":"10.3390\/biomedicines13102429","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T11:42:49Z","timestamp":1759750969000},"page":"2429","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effects of Janus Kinase Inhibitors on Rheumatoid Arthritis Pain: Clinical Evidence and Mechanistic Pathways"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7848-6600","authenticated-orcid":false,"given":"Andrej","family":"Belan\u010di\u0107","sequence":"first","affiliation":[{"name":"Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, Bra\u0107e Branchetta 20, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1564-8996","authenticated-orcid":false,"given":"Seher","family":"Sener","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, Adana City Training and Research Hospital, Adana 01370, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf Ziya","family":"Sener","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, 3000 CB Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3722-9701","authenticated-orcid":false,"given":"Almir","family":"Fajki\u0107","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Faculty of Medicine, University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijana","family":"Vu\u010dkovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology and Dialysis, University Hospital of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0410-542X","authenticated-orcid":false,"given":"Antonio","family":"Markoti\u0107","sequence":"additional","affiliation":[{"name":"Department of Physiology, School of Medicine, University of Mostar, 88000 Mostar, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana Stani\u0107","family":"Beni\u0107","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, General Hospital \u201cDr. Josip Ben\u010devi\u0107\u201d Slavonski Brod, Andrije \u0160tampara 42, 35000 Slavonski Brod, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9351-9669","authenticated-orcid":false,"given":"Ines","family":"Poto\u010dnjak","sequence":"additional","affiliation":[{"name":"Institute for Clinical Medical Research and Education, Sestre Milosrdnice University Hospital Center, School of Medicine Catholic University of Croatia, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija Rogoznica","family":"Pavlovi\u0107","sequence":"additional","affiliation":[{"name":"Hospital for Medical Rehabilitation of Heart and Lung Diseases and Rheumatism \u2018Thalassotherapia-Opatija\u2019, 51410 Opatija, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-7597","authenticated-orcid":false,"given":"Josipa","family":"Radi\u0107","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology and Dialysis, University Hospital of Split, 21000 Split, Croatia"},{"name":"Internal Medicine Department, School of Medicine, University of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0350-6800","authenticated-orcid":false,"given":"Mislav","family":"Radi\u0107","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, School of Medicine, University of Split, 21000 Split, Croatia"},{"name":"Department of Internal Medicine, Division of Rheumatology, Allergology and Clinical Immunology, Center of Excellence for Systemic Sclerosis in Croatia, University Hospital of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.hcl.2010.09.002","article-title":"Advances in the medical treatment of rheumatoid arthritis","volume":"27","author":"Kahlenberg","year":"2011","journal-title":"Hand Clin."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Mohammed, R.H.A. (2020). Understanding the Mechanisms of Pain in Rheumatoid Arthritis. Rheumatoid Arthritis\u2014Other Perspectives towards a Better Practice, IntechOpen.","DOI":"10.5772\/intechopen.81489"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4078\/jrd.22.0047","article-title":"A Challenging Target: Persistent Pain During the Remission State in Rheumatoid Arthritis Patients","volume":"30","author":"Lim","year":"2023","journal-title":"J. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2217\/pmt.16.4","article-title":"Pain in rheumatoid arthritis: Models and mechanisms","volume":"6","author":"Bas","year":"2016","journal-title":"Pain Manag."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11926-024-01159-4","article-title":"How to Distinguish Non-Inflammatory from Inflammatory Pain in RA?","volume":"26","author":"Khot","year":"2024","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3899\/jrheum.230158","article-title":"Inflammatory and Noninflammatory Disease Activity in Rheumatoid Arthritis: The Effect of Pain on Personalized Medicine","volume":"50","author":"McWilliams","year":"2023","journal-title":"J. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.31083\/j.jin2305089","article-title":"The Complexity of Neuropathic Pain and Central Sensitization: Exploring Mechanisms and Therapeutic Prospects","volume":"23","author":"Ma","year":"2024","journal-title":"J. Integr. Neurosci."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Yang, J.X., Wang, H.F., Chen, J.Z., Li, H.Y., Hu, J.C., Yu, A.A., Wen, J.J., Chen, S.J., Lai, W.D., and Wang, S. (2022). Potential Neuroimmune Interaction in Chronic Pain: A Review on Immune Cells in Peripheral and Central Sensitization. Front. Pain Res., 3.","DOI":"10.3389\/fpain.2022.946846"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/ALN.0000000000002130","article-title":"Neuroinflammation and Central Sensitization in Chronic and Widespread Pain","volume":"129","author":"Ji","year":"2018","journal-title":"Anesthesiology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1759720X18776224","article-title":"The role of the JAK\/STAT signal pathway in rheumatoid arthritis","volume":"10","author":"Malemud","year":"2018","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_13","first-page":"3498","article-title":"JAK\/STAT pathway in pathology of rheumatoid arthritis (Review)","volume":"20","author":"Ciobanu","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","article-title":"JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data","volume":"13","author":"Harrington","year":"2020","journal-title":"J. Inflamm. Res."},{"key":"ref_15","first-page":"430","article-title":"Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: Results of two Phase 2 randomised controlled trials","volume":"34","author":"Wallenstein","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Taylor, P.C., Lee, Y.C., Fleischmann, R., Takeuchi, T., Perkins, E.L., Fautrel, B., Zhu, B., Quebe, A.K., Gaich, C.L., and Zhang, X. (2019). Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: Results from the RA-BEAM trial. J. Clin. Med., 8.","DOI":"10.3390\/jcm8060831"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"eadk3506","DOI":"10.1126\/scitranslmed.adk3506","article-title":"Synovial fibroblast gene expression is associated with sensory nerve growth and pain in rheumatoid arthritis","volume":"16","author":"Bai","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1097\/j.pain.0000000000001890","article-title":"Sensitization of knee-innervating sensory neurons by tumor necrosis factor-\u03b1-activated fibroblast-like synoviocytes: An in vitro, coculture model of inflammatory pain","volume":"161","author":"Chakrabarti","year":"2020","journal-title":"Pain"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hall, B.E., Mazhar, K., Macdonald, E., Cassidy, M., Doty, M., Judkins, C., Terse, A., Shiers, S., Tadros, S., and Yun, S. (2024). Transcriptome analysis of rheumatoid arthritis uncovers genes linked to inflammation-induced pain. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-77212-0"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/art.42429","article-title":"The Biology of Pain: Through the Rheumatology Lens","volume":"75","author":"Sunzini","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"123361","DOI":"10.1016\/j.lfs.2024.123361","article-title":"Pain in rheumatoid arthritis: Emerging role of high mobility group box 1 protein-HMGB1","volume":"362","author":"Krishna","year":"2025","journal-title":"Life Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41584-024-01155-z","article-title":"An interdisciplinary perspective on peripheral drivers of pain in rheumatoid arthritis","volume":"20","author":"Kirkham","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11914-018-0473-5","article-title":"Mechanisms for Joint Pain in Rheumatoid Arthritis (RA): From Cytokines to Central Sensitization","volume":"16","author":"Zhang","year":"2018","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8564215","DOI":"10.1155\/2018\/8564215","article-title":"Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets-A Focus on the JAK-STAT Pathway","volume":"2018","author":"Salaffi","year":"2018","journal-title":"Pain Res. Manag."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/art.37739","article-title":"Central pain mechanisms in the rheumatic diseases: Future directions","volume":"65","author":"Phillips","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10067-019-04749-1","article-title":"The important role of central sensitization in chronic musculoskeletal pain seen in different rheumatic diseases","volume":"39","author":"Guler","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Kraev, K., Geneva-Popova, M., Hristov, B., Uchikov, P., Popova, S., Kraeva, M., Basheva-Kraeva, Y., Sheytanov, I., Petranova, T., and Stoyanova, N. (2023). Exploring the Novel Dimension of Immune Interactions in Pain: JAK Inhibitors\u2019 Pleiotropic Potential. Life, 13.","DOI":"10.3390\/life13101994"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41375-025-02569-8","article-title":"Malignant JAK-signaling: At the interface of inflammation and malignant transformation","volume":"39","author":"Perner","year":"2025","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaci.2024.09.020","article-title":"JAK-STAT signaling pathway, immunodeficiency, inflammation, immune dysregulation, and inborn errors of immunity","volume":"155","author":"Samra","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: Much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1535-7163.MCT-22-0323","article-title":"JAK: Not Just Another Kinase","volume":"21","author":"Agashe","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1158\/1078-0432.CCR-13-0279","article-title":"Molecular pathways: Molecular basis for sensitivity and resistance to JAK kinase inhibitors","volume":"20","author":"Meyer","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"106362","DOI":"10.1016\/j.phrs.2022.106362","article-title":"Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders","volume":"183","author":"Roskoski","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Liongue, C., Ratnayake, T., Basheer, F., and Ward, A.C. (2024). Janus Kinase 3 (JAK3): A Critical Conserved Node in Immunity Disrupted in Immune Cell Cancer and Immunodeficiency. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052977"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kie\u0142bowski, K., Plewa, P., Bratborska, A.W., Bakinowska, E., and Pawlik, A. (2024). JAK Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25158327"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"104951","DOI":"10.1016\/j.yexmp.2024.104951","article-title":"Modulation of IL-6 receptor\/STAT3 downstream signaling in rheumatoid arthritis patients","volume":"141","author":"Cacciapaglia","year":"2025","journal-title":"Exp. Mol. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/rheumatology\/keab024","article-title":"JAK1: Number one in the family; number one in inflammation?","volume":"60","author":"Spinelli","year":"2021","journal-title":"Rheumatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"110238","DOI":"10.1016\/j.clim.2024.110238","article-title":"JAK\/STAT signaling in rheumatoid arthritis leukocytes is uncoupled from serum cytokines in a subset of patients","volume":"264","author":"Dreo","year":"2024","journal-title":"Clin. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ghouri, M., Siddiqui, N.N., Lateef, M., Avesi, L., Khan, R., Ghauri, H., Asif, E., and Zehra, S. (2025). Modified expression of JAK-STAT pathway genes in an in vivo rheumatoid arthritis model: A preclinical study to explore genetic insights. Biochim. Biophys. Acta Mol. Basis Dis., 1871.","DOI":"10.1016\/j.bbadis.2025.167780"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ptacek, J., Hawtin, R.E., Sun, D., Louie, B., Evensen, E., Mittleman, B.B., Cesano, A., Cavet, G., Bingham, C.O., and Cofield, S.S. (2021). Diminished cytokine-induced Jak\/STAT signaling is associated with rheumatoid arthritis and disease activity. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0244187"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/annrheumdis-2014-205850","article-title":"IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis","volume":"75","author":"Anderson","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/rheumatology\/kex391","article-title":"Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis","volume":"57","author":"Choy","year":"2018","journal-title":"Rheumatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s13075-014-0470-8","article-title":"Nociceptive neurons detect cytokines in arthritis","volume":"16","author":"Schaible","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/art.34384","article-title":"Spinal interleukin-6 is an amplifier of arthritic pain in the rat","volume":"64","author":"Vazquez","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/art.22282","article-title":"Sensitization of unmyelinated sensory fibers of the joint nerve to mechanical stimuli by interleukin-6 in the rat: An inflammatory mechanism of joint pain","volume":"56","author":"Brenn","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coi.2015.02.008","article-title":"The IL-6\/gp130\/STAT3 signaling axis: Recent advances towards specific inhibition","volume":"34","author":"Garbers","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13075-024-03354-1","article-title":"Baricitinib ameliorates inflammatory and neuropathic pain in collagen antibody-induced arthritis mice by modulating the IL-6\/JAK\/STAT3 pathway and CSF-1 expression in dorsal root ganglion neurons","volume":"26","author":"Makabe","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nrn.2018.2","article-title":"Microglia in neuropathic pain: Cellular and molecular mechanisms and therapeutic potential","volume":"19","author":"Inoue","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Vazquez, E., Richter, F., Natura, G., Konig, C., Eitner, A., and Schaible, H.G. (2024). Direct Effects of the Janus Kinase Inhibitor Baricitinib on Sensory Neurons. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252211943"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ard.2025.01.005","article-title":"Characterisation of the antinociceptive effect of baricitinib in the collagen antibody-induced arthritis mouse model","volume":"84","author":"Simon","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"176403","DOI":"10.1016\/j.ejphar.2024.176403","article-title":"Ruxolitinib attenuates microglial inflammatory response by inhibiting NF-kappaB\/MAPK signaling pathway","volume":"968","author":"Min","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1093\/rheumatology\/kead013","article-title":"Inhibitory effect of baricitinib on microglia and STAT3 in a region with a weak blood-brain barrier in a mouse model of rheumatoid arthritis","volume":"62","author":"Matsushita","year":"2023","journal-title":"Rheumatology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12974-019-1524-2","article-title":"An update on reactive astrocytes in chronic pain","volume":"16","author":"Li","year":"2019","journal-title":"J. Neuroinflamm."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/brain\/awr025","article-title":"JAK-STAT3 pathway regulates spinal astrocyte proliferation and neuropathic pain maintenance in rats","volume":"134","author":"Tsuda","year":"2011","journal-title":"Brain"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"186","DOI":"10.14336\/AD.2023.0515","article-title":"Targeting the JAK2\/STAT3 signaling pathway for chronic pain","volume":"15","author":"Dai","year":"2024","journal-title":"Aging Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.pain.2011.01.054","article-title":"Leptin enhances NMDA-induced spinal excitation in rats: A functional link between adipocytokine and neuropathic pain","volume":"152","author":"Tian","year":"2011","journal-title":"Pain"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.semarthrit.2020.10.008","article-title":"The Jak\/STAT pathway: A focus on pain in rheumatoid arthritis","volume":"51","author":"Simon","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/annrheumdis-2012-201703","article-title":"Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain","volume":"72","author":"Cook","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/j.pain.0000000000001130","article-title":"Central inhibition of granulocyte-macrophage colony-stimulating factor is analgesic in experimental neuropathic pain","volume":"159","author":"Nicol","year":"2018","journal-title":"Pain"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1523\/JNEUROSCI.2204-18.2019","article-title":"Transcriptional Regulation of Voltage-Gated Sodium Channels Contributes to GM-CSF-Induced Pain","volume":"39","author":"Zhang","year":"2019","journal-title":"J. Neurosci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/annrheumdis-2024-eular.4456","article-title":"POS1148 Mechanisms of Pain Modulation by JAK Inhibition: Upadacitinib Regulates Pain-Related Pathways and Bdnf Expression in Microglial Cells","volume":"83","author":"Navarini","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Li, T., Li, L., Peng, R., Hao, H., Zhang, H., Gao, Y., Wang, C., Li, F., Liu, X., and Chen, F. (2022). Abrocitinib Attenuates Microglia-Mediated Neuroinflammation after Traumatic Brain Injury via Inhibiting the JAK1\/STAT1\/NF-kappaB Pathway. Cells, 11.","DOI":"10.3390\/cells11223588"},{"key":"ref_66","first-page":"2155","article-title":"Crosstalk Between IL-6 and TNF-Alpha Signaling Pathway in Rheumatoid Arthritis Synovial Fibroblasts","volume":"68","author":"Valin","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.bbi.2006.10.010","article-title":"Interleukin-6 mediates low-threshold mechanical allodynia induced by intrathecal HIV-1 envelope glycoprotein gp120","volume":"21","author":"Ledeboer","year":"2007","journal-title":"Brain Behav. Immun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/rheumatology\/kes131","article-title":"Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: Results from the 24-week randomized controlled RADIATE study","volume":"51","author":"Strand","year":"2012","journal-title":"Rheumatology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-018-1614-z","article-title":"Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis","volume":"20","author":"Strand","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"eabq4419","DOI":"10.1126\/scitranslmed.abq4419","article-title":"Additive efficacy of a bispecific anti-TNF\/IL-6 nanobody compound in translational models of rheumatoid arthritis","volume":"15","author":"Biesemann","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/mr\/roac083","article-title":"Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients na\u00efve to MTX treatment (FINCH 3)","volume":"33","author":"Atsumi","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Cai, W., Tong, R., Sun, Y., Yao, Y., and Zhang, J. (2024). Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: A systematic review and network meta-analysis of randomized controlled trials. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1387585"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10787-015-0232-5","article-title":"A history of the term \u201cDMARD\u201d","volume":"23","author":"Buer","year":"2015","journal-title":"Inflammopharmacology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","article-title":"Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European Leflunomide Study Group","volume":"353","author":"Smolen","year":"1999","journal-title":"Lancet"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/rheumatology\/41.12.1367","article-title":"The rheumatoid arthritis patient in the clinic: Comparing more than 1300 consecutive DMARD courses","volume":"41","author":"Aletaha","year":"2002","journal-title":"Rheumatology"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Lin, Y.J., Anzaghe, M., and Sch\u00fclke, S. (2020). Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. Cells, 9.","DOI":"10.3390\/cells9040880"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s40259-018-0320-3","article-title":"Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What\u2019s the Difference?","volume":"32","author":"Avci","year":"2018","journal-title":"BioDrugs"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nbt0113-3","article-title":"Pfizer\u2019s first-in-class JAK inhibitor pricey for rheumatoid arthritis market","volume":"31","author":"Garber","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s40265-020-01439-0","article-title":"Filgotinib: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.revmed.2024.10.452","article-title":"JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases","volume":"46","author":"Chikhoune","year":"2025","journal-title":"Rev. Med. Interne."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): A double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/ejp.1651","article-title":"The burden of pain in rheumatoid arthritis: Impact of disease activity and psychological factors","volume":"24","author":"Pouplin","year":"2020","journal-title":"Eur. J. Pain"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00393-020-00889-x","article-title":"Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-na\u00efve patients with rheumatoid arthritis","volume":"80","author":"Sung","year":"2021","journal-title":"Z. Rheumatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1159\/000527186","article-title":"Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis","volume":"108","author":"Lee","year":"2023","journal-title":"Pharmacology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e001994","DOI":"10.1136\/rmdopen-2021-001994","article-title":"Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy","volume":"8","author":"Taylor","year":"2022","journal-title":"RMD Open"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in Patients with Refractory Rheumatoid Arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13075-017-1410-1","article-title":"Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"19","author":"Schiff","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Fautrel, B., Kirkham, B., Pope, J.E., Takeuchi, T., Gaich, C., Quebe, A., Zhu, B., de la Torre, I., De Leonardis, F., and Taylor, P.C. (2019). Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM. J. Clin. Med., 8.","DOI":"10.3390\/jcm8091394"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial","volume":"72","author":"Takeuchi","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e001621","DOI":"10.1136\/rmdopen-2021-001621","article-title":"Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: Post hoc analysis of FINCH 3","volume":"7","author":"Aletaha","year":"2021","journal-title":"RMD Open"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrrheum.2014.64","article-title":"Mechanisms, impact and management of pain in rheumatoid arthritis","volume":"10","author":"Walsh","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11916-021-00973-0","article-title":"Chronic pain in patients with rheumatoid arthritis","volume":"25","author":"Mathias","year":"2021","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Almoallim, H.M., Omair, M.A., Ahmed, S.A., Vidyasagar, K., Sawaf, B., and Yassin, M.A. (2025). Comparative Efficacy and Safety of JAK Inhibitors in the Management of Rheumatoid Arthritis: A Network Meta-Analysis. Pharmaceuticals, 18.","DOI":"10.3390\/ph18020178"},{"key":"ref_99","first-page":"32","article-title":"Molecular target and therapeutic aspects of rheumatoid arthritis: A review","volume":"8","author":"Das","year":"2015","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2016.175","article-title":"Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers","volume":"12","author":"Brown","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","article-title":"Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review","volume":"158","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.43014","article-title":"Effectiveness of JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results From a Nationwide Swedish Cohort Study","volume":"77","author":"Eberhard","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): A phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): A randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"108794","DOI":"10.1016\/j.intimp.2022.108794","article-title":"An update on novel therapeutic intervention in Rheumatoid arthritis","volume":"109","author":"Shah","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1759720X221114101","DOI":"10.1177\/1759720X221114101","article-title":"Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: Optimising treatment outcomes","volume":"14","author":"Taylor","year":"2022","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Vasconcelos, D.P., Jabangwe, C., Lamghari, M., and Alves, C.J. (2022). The neuroimmune interplay in joint pain: The role of macrophages. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.812962"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/eci.10.2","article-title":"The AMBITION trial: Tocilizumab monotherapy for rheumatoid arthritis","volume":"6","author":"Jones","year":"2010","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/rheumatology\/keaa893","article-title":"Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis","volume":"60","author":"Avci","year":"2021","journal-title":"Rheumatology"},{"key":"ref_111","first-page":"79","article-title":"Janus Kinase Inhibitors (JAK) As Potential Candidate Targets to Rheumatoid Arthritis","volume":"2","author":"Rathi","year":"2025","journal-title":"Curr. Res. Altern. Complement. Integr. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/14712598.2022.2130243","article-title":"Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis","volume":"22","author":"Alciati","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e002012","DOI":"10.1136\/rmdopen-2021-002012","article-title":"Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: Results through 3 years from the SELECT-COMPARE study","volume":"8","author":"Fleischmann","year":"2022","journal-title":"RMD Open"},{"key":"ref_114","first-page":"53","article-title":"Efficacy and safety of filgotinib in patients with high risk of poor prognosis who showed inadequate response to MTX: A post hoc analysis of the FINCH 1 study","volume":"10","author":"Combe","year":"2023","journal-title":"Rheumatol. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s40744-024-00694-x","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis refractory to biologic DMARDs: Results through week 216 from the SELECT-CHOICE study","volume":"11","author":"Kato","year":"2024","journal-title":"Rheumatol. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1759720x21999564","DOI":"10.1177\/1759720X21999564","article-title":"Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: A systematic review and network meta-analysis","volume":"13","author":"Weng","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3899\/jrheum.141575","article-title":"Patients with rheumatoid arthritis in the Australian OPAL cohort show significant improvement in disease activity over 5 years: A multicenter observational study","volume":"42","author":"Littlejohn","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40744-017-0078-y","article-title":"Discontinuation of biologic therapy in rheumatoid arthritis: Analysis from the Corrona RA Registry","volume":"4","author":"Strand","year":"2017","journal-title":"Rheumatol. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1007\/s12325-023-02619-6","article-title":"One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib","volume":"40","author":"Bergman","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/09540260050007408","article-title":"DSM-IV pain disorder: A case against the diagnosis","volume":"12","author":"Sullivan","year":"2000","journal-title":"Int. Rev. Psychiatry"},{"key":"ref_121","first-page":"848","article-title":"Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: Patient-reported outcomes from the 24-month Phase 3 ORAL Scan study","volume":"38","author":"Strand","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3899\/jrheum.2023-1062","article-title":"Upadacitinib in rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: Efficacy and safety through 5 years (SELECT-NEXT)","volume":"51","author":"Burmester","year":"2024","journal-title":"J. Rheumatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","article-title":"Efficacy and safety of JAK inhibitors in rheumatoid arthritis: Update for the practising clinician","volume":"20","author":"Szekanecz","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40273-014-0174-6","article-title":"The burden of disease in rheumatoid arthritis","volume":"32","author":"Uhlig","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/ar3353","article-title":"Pain persists in DAS28 rheumatoid arthritis remission but not in ACR\/EULAR remission: A longitudinal observational study","volume":"13","author":"Lee","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bbi.2020.06.023","article-title":"Brain TNF drives post-inflammation depression-like behavior and persistent pain in experimental arthritis","volume":"89","author":"Lopes","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"T\u00f3th, L., Juh\u00e1sz, M.F., Szab\u00f3, L., Abada, A., Kiss, F., Hegyi, P., Farkas, N., Nagy, G., and Helyes, Z. (2022). Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031246"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/acr.24264","article-title":"Pain Over Two Years After Start of Biologic Versus Conventional Combination Treatment in Early Rheumatoid Arthritis: Results From a Swedish Randomized Controlled Trial","volume":"73","author":"Olofsson","year":"2021","journal-title":"Arthritis Care Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/acr.22790","article-title":"Remaining Pain in Early Rheumatoid Arthritis Patients Treated With Methotrexate","volume":"68","author":"Altawil","year":"2016","journal-title":"Arthritis Care Res."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Mahmood, N., Mihalcioiu, C., and Rabbani, S.A. (2018). Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00024"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/rheumatology\/kex080","article-title":"No clear association between ultrasound remission and health status in rheumatoid arthritis patients in clinical remission","volume":"56","author":"Kuijper","year":"2017","journal-title":"Rheumatology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/art.34543","article-title":"Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity","volume":"64","author":"Studenic","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/15360288.2021.1973647","article-title":"Pain Management Strategies in Rheumatoid Arthritis: A Narrative Review","volume":"35","author":"Valero","year":"2021","journal-title":"J. Pain Palliat. Care Pharmacother."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Benucci, M., Gobbi, F.L., Fusi, P., Damiani, A., Russo, E., Guiducci, S., Manfredi, M., Grossi, V., Infantino, M., and Amedei, A. (2023). Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis. Front. Biosci., 28.","DOI":"10.31083\/j.fbl2808176"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"102506","DOI":"10.1016\/j.autrev.2020.102506","article-title":"Precision medicine in the care of rheumatoid arthritis: Focus on prediction and prevention of future clinically-apparent disease","volume":"19","author":"Mahler","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.trsl.2021.02.007","article-title":"Serum levels of the soluble urokinase plasminogen activator receptor (suPAR) correlates with disease activity in early rheumatoid arthritis and reflects joint damage over time","volume":"232","author":"Enocsson","year":"2021","journal-title":"Transl. Res."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Inciarte-Mundo, J., Frade-Sosa, B., and Sanmart\u00ed, R. (2022). From bench to bedside: Calprotectin (S100A8\/S100A9) as a biomarker in rheumatoid arthritis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1001025"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Angelini, J., Talotta, R., Roncato, R., Fornasier, G., Barbiero, G., Dal Cin, L., Brancati, S., and Scaglione, F. (2020). JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future. Biomolecules, 10.","DOI":"10.3390\/biom10071002"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/rheumatology\/key256","article-title":"Clinical efficacy of new JAK inhibitors under development. Just more of the same?","volume":"58","author":"Westhovens","year":"2019","journal-title":"Rheumatology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2217\/imt-2018-0178","article-title":"Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: A systemic literature review","volume":"11","author":"Jegatheeswaran","year":"2019","journal-title":"Immunotherapy"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: A randomised, double-blind, placebo-controlled phase III trial (RAJ3)","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: Results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: Results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/bloodadvances.2019001043","article-title":"A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease","volume":"4","author":"Schroeder","year":"2020","journal-title":"Blood Adv."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"101970","DOI":"10.1016\/j.berh.2024.101970","article-title":"Inflammatory or non-inflammatory pain in inflammatory arthritis\u2014How to differentiate it?","volume":"38","author":"Pellegrino","year":"2024","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/ard.2006.064287","article-title":"Pain and psychological health status over a 10-year period in patients with recent onset rheumatoid arthritis","volume":"66","author":"Finset","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_148","first-page":"101","article-title":"Enhancing Rheumatoid Arthritis Treatment by Subcutaneous Methotrexate Injections and Anti-IL-2 Antibody Synthesis","volume":"13","author":"Sagheer","year":"2024","journal-title":"Int. J. Agric. Biosci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"91","DOI":"10.47278\/journal.abr\/2024.003","article-title":"Cell membrane coated polymeric nanocarriers: A novel drug delivery approach for the targeted therapy of rheumatoid arthritis","volume":"15","author":"Iqbal","year":"2024","journal-title":"Agrobiol. Rec."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/10\/2429\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:31:18Z","timestamp":1760016678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/10\/2429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,5]]},"references-count":149,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["biomedicines13102429"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13102429","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,5]]}}}